Allogene Therapeutics
Lyubov Efros is an accomplished scientist with extensive experience in the biopharmaceutical industry, currently serving as a Scientist at Allogene Therapeutics since February 2019. Previously, Lyubov worked at Pfizer as a Cell and Gene Therapy Technical Development Scientist, focusing on CAR-T therapeutics. Prior roles include Senior Scientist at BD Biosciences, where significant contributions were made to the EuroFlow™ Consortium and the development of diagnostic systems for hematological malignancies and HIV/AIDS care. Earlier experience includes positions as Senior Research Associate at PDL BioPharma, and Research Associate at RPR GENCELL, specializing in immunology and gene transfection. Lyubov began the career at Caltag and holds a BS and MS in Chemistry from Kharkov Polytechnic University, Ukraine.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.